StockData
Neurogene Inc. logo

Neurogene Inc. (NGNE) stock

NGNENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$23.10−0.20 (-0.86%)

Close on Nov 17, 2026Market cap $462.26MP/E –Yield –

Neurogene enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Neurogene's enterprise value was $171.95M on Nov 11, 2026, against $45.71M a year earlier. Over the last 5 years it ranged from -$138.45M to $1.08B, with a median of $94.86M.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$171.95M+345.2%
2025Dec 31, 2025$38.62M-75.6%
2024Dec 31, 2024$158.10M+120.2%
2023Dec 29, 2023$71.80M–
2022Dec 30, 2022-$21.03M-103.2%
2021Dec 31, 2021$662.21M-69.3%
2020Dec 31, 2020$2.16B+63.6%
2019Dec 31, 2019$1.32B+1032.1%
2018Dec 31, 2018$116.63M-89.0%
2017Dec 29, 2017$1.06B-27.7%
2016Dec 30, 2016$1.46B+94.8%
2015Dec 31, 2015$749.85M+413.1%
2014Dec 31, 2014$146.15M–

More Neurogene figures

See a number that looks wrong?